Different Features of ¹⁸F-FAPI, ¹⁸F-FDG PET/CT and MRI in the Evaluation of Extrahepatic Metastases and Local Recurrent Hepatocellular Carcinoma (HCC): A Case Report and Review of the Literature

References

• Maldonado A, González-Alenda FJ, Alonso M, Sierra JM. PET-CT in clinical oncology. Clin Transl Oncol. 2007;9(8):494–505. doi:10.1007/s12094-007-0093-5
   PubMed Web of Science ®Google Scholar
• Lee SM, Kim HS, Lee S, Lee JW. Emerging role of 18F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma. World J Gastroenterol. 2019;25(11):1289–1306. doi:10.3748/wjg.v25.i11.1289
   PubMed Web of Science ®Google Scholar
• Haug AR. Imaging of primary liver tumors with positron-emission tomography. Q J Nucl Med Mol Imaging. 2017;61(3):292–300. doi:10.23736/S1824-4785.17.02994-6
   PubMed Web of Science ®Google Scholar
• Hayakawa N, Nakamoto Y, Nakatani K, et al. Clinical utility and limitations of FDG PET in detecting recurrent hepatocellular carcinoma in postoperative patients. Int J Clin Oncol. 2014;19(6):1020–1028. doi:10.1007/s10147-013-0653-3
   PubMed Web of Science ®Google Scholar
• Dubash SR, Idowu OA, Sharma R. The emerging role of positron emission tomography in hepatocellular carcinoma. Hepat Oncol. 2015;2(2):191–200. doi:10.2217/hep.15.6
   PubMedGoogle Scholar
• Tovoli F, Renzulli M, Negrini G, et al. Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib. Eur Radiol. 2018;28(9):3611–3620. doi:10.1007/s00330-018-5393-3
   PubMed Web of Science ®Google Scholar
• Talbot JN, Fartoux L, Balogova S, et al. Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med. 2010;51(11):1699–1706. doi:10.2967/jnumed.110.075507
   PubMed Web of Science ®Google Scholar
• Khan MA, Combs CS, Brunt EM, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol. 2000;32(5):792–797. doi:10.1016/S0168-8278(00)80248-2
   PubMed Web of Science ®Google Scholar
• Verhoef C, Valkema R, de Man RA, Krenning EP, Yzermans JN. Fluorine-18 FDG imaging in hepatocellular carcinoma using positron coincidence detection and single photon emission computed tomography. Liver. 2002;22(1):51–56. doi:10.1046/j.0106-9543.2001.01593.x
   PubMedGoogle Scholar
• Sun HC, Tang ZY. Preventive treatments for recurrence after curative resection of hepatocellular carcinoma – a literature review of randomized control trials. World J Gastroenterol. 2003;9(4):635–640. doi:10.3748/wjg.v9.i4.635
   PubMed Web of Science ®Google Scholar
• Guiu B, Minello A, Cottet V, et al. A 30-year, population-based study shows improved management and prognosis of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2010;8(11):986–991. doi:10.1016/j.cgh.2010.07.018
   PubMed Web of Science ®Google Scholar
• Zhou XD. Recurrence and metastasis of hepatocellular carcinoma: progress and prospects. Hepatobiliary Pancreat Dis Int. 2002;1(1):35–41.
   PubMedGoogle Scholar
• Teefey SA, Hildeboldt CC, Dehdashti F, et al. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology. 2003;226(2):533–542. doi:10.1148/radiol.2262011980
   PubMed Web of Science ®Google Scholar
• Cheung TT, Chan SC, Ho CL, et al. Can positron emission tomography with the dual tracers [11 C]acetate and [18 F]fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma? Liver Transpl. 2011;17(10):1218–1225. doi:10.1002/lt.22362
   PubMed Web of Science ®Google Scholar
• Chen H, Teng M, Zhang H, Liang X, Cheng H, Liu G. Advanced radionuclides in diagnosis and therapy for hepatocellular carcinoma. Chin Chem Lett. 2022;33(7):3371–3383. doi:10.1016/j.cclet.2022.03.079
   Web of Science ®Google Scholar
• Loktev A, Lindner T, Mier W, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59(9):1423–1429. doi:10.2967/jnumed.118.210435
   PubMed Web of Science ®Google Scholar
• Giesel FL, Kratochwil C, Lindner T, et al. 68Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60(3):386–392. doi:10.2967/jnumed.118.215913
   PubMed Web of Science ®Google Scholar
• Hathi DK, Jones EF. 68Ga FAPI PET/CT: tracer uptake in 28 different kinds of cancer. Radiol Imaging Cancer. 2019;1(1):e194003. doi:10.1148/rycan.2019194003
   PubMedGoogle Scholar
• Röhrich M, Loktev A, Wefers AK, et al. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT. Eur J Nucl Med Mol Imaging. 2019;46(12):2569–2580. doi:10.1007/s00259-019-04444-y
   PubMed Web of Science ®Google Scholar
• Chen H, Pang Y, Wu J, et al. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020;47(8):1820–1832. doi:10.1007/s00259-020-04769-z
   PubMed Web of Science ®Google Scholar
• Windisch P, Röhrich M, Regnery S, et al. Fibroblast Activation Protein (FAP) specific PET for advanced target volume delineation in glioblastoma. Radiother Oncol. 2020;150:159–163. doi:10.1016/j.radonc.2020.06.040
   PubMed Web of Science ®Google Scholar
• Ristau J, Giesel FL, Haefner MF, et al. Impact of primary staging with fibroblast activation protein specific enzyme inhibitor (FAPI)-PET/CT on radio-oncologic treatment planning of patients with esophageal cancer. Mol Imaging Biol. 2020;22(6):1495–1500. doi:10.1007/s11307-020-01548-y
   PubMed Web of Science ®Google Scholar
• Shi X, Xing H, Yang X, et al. Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET/CT: a pilot study in patients with suspected hepatic nodules. Eur J Nucl Med Mol Imaging. 2021;48(1):196–203. doi:10.1007/s00259-020-04882-z
   PubMed Web of Science ®Google Scholar
• Shi X, Xing H, Yang X, et al. Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study. Eur J Nucl Med Mol Imaging. 2021;48(5):1593–1603. doi:10.1007/s00259-020-05070-9
   PubMed Web of Science ®Google Scholar
• Guo W, Pang Y, Yao L, et al. Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2021;48(5):1604–1617. doi:10.1007/s00259-020-05095-0
   PubMed Web of Science ®Google Scholar
• Geist BK, Xing H, Wang J, et al. A methodological investigation of healthy tissue, hepatocellular carcinoma, and other lesions with dynamic 68Ga-FAPI-04 PET/CT imaging. EJNMMI Phys. 2021;8(1):8. doi:10.1186/s40658-021-00353-y
   PubMed Web of Science ®Google Scholar
• Röhrich M, Naumann P, Giesel FL, et al. Impact of 68Ga-FAPI PET/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas. J Nucl Med. 2021;62(6):779–786. doi:10.2967/jnumed.120.253062
   PubMed Web of Science ®Google Scholar
• Wang H, Zhu W, Ren S, et al. 68Ga-FAPI-04 versus 18F-FDG PET/CT in the detection of hepatocellular carcinoma. Front Oncol. 2021;11:693640. doi:10.3389/fonc.2021.693640
   PubMed Web of Science ®Google Scholar
• Chen H, Zhao L, Ruan D, et al. Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings. Eur J Nucl Med Mol Imaging. 2021;48(1):73–86. doi:10.1007/s00259-020-04940-6
   PubMed Web of Science ®Google Scholar
• Sugiyama M, Sakahara H, Torizuka T, et al. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol. 2004;39(10):961–968. doi:10.1007/s00535-004-1427-5
   PubMed Web of Science ®Google Scholar
• Bayraktutan U, Ogul H, Kantarci M, Karaca L, Pirimoglu B. Education and imaging. Hepatobiliary and pancreatic: calcified perihepatic and capsular metastases. J Gastroenterol Hepatol. 2014;29(4):664. doi:10.1111/jgh.12533
   PubMed Web of Science ®Google Scholar
• Peng D, He J, Liu H, Cao J, Wang Y, Chen Y. FAPI PET/CT research progress in digestive system tumours. Dig Liver Dis. 2022;54(2):164–169. doi:10.1016/j.dld.2021.07.011
   PubMedGoogle Scholar